« Back
Home /
Refametinib

Refametinib

Item no.	HY-14691-100mg
Manufacturer	MedChem Express
CASRN	923032-37-5
Amount	100 mg
Quantity options	100 mg 10mM/1mL 10 mg 50 mg 5 mg
Category	Oncology Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Skin Cancer Colorectal Cancer Hepatic Cancer
Type	Inhibitors
Specific against	other
Purity	99.82
Formula	C19H20F3IN2O5S
Citations	[1]Iverson C, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 2009 Sep 1;69(17):6839-47.
Smiles	O=S(C1(C[C@H](O)CO)CC1)(NC(C(NC(C(F)=C2)=CC=C2I)=C3F)=C(OC)C=C3F)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	BAY 869766; RDEA119
Available
Product Description	Refametinib (BAY 869766; RDEA119) is an orally available, potent, non-ATP-competitive, selective, allosteric MEK1/MEK2 inhibitor with IC50s of 19 nM and 47 nM, respectively.
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	572.34
Clinical Information	Phase 3
Manufacturers Research Area	Cancer
Solubility	DMSO : ≥ 31 mg/mL
Target	MEK
Manufacturers Target	MEK
Isoform	MEK1; MEK2
Manufacturers Pathway	MAPK/ERK Pathway
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-14691-100mg-safety-datasheet.pdf